Neoadjuvant trastuzumab rezetecan in HER2-positive breast cancer
The third generation HER2-directed antibody-drug conjugate trastuzumab rezetecan showed robust activity with a tolerable safety profile in a neoadjuvant setting in HER2-positive breast cancer